
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Lexington, MA-Indevus Pharmaceuticals announced that trospium chloride (Sanctura) has been approved by the FDA for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.





